{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"

PRODIGE\n107- ENGIC 01- COLOSOTO

\n\n

A single-arm phase II\nstudy evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib\n(KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a\ndoublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated\ncolorectal adenocarcinoma

","eudractNumber":"2024-514030-20-00","id":11576,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2026-02-04T14:05:28+01:00","shortTitle":"PRODIGE 107-COLOSOTO","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
Pre-Operative Treatment in rEseCTable cOlon canceR
(PROTECTOR/FIRE-10; AIO KRK0620; IAG-VO-0323)
Prospective, randomized, open, multicenter Phase III trial
to investigate the efficacy preoperative systemic therapy in
advanced colon cancer
","eudractNumber":"2023-508076-11-00","id":11330,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-01T09:01:01+02:00","shortTitle":"PROTECTOR/ Fire-10","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Erstellung eines immunhistochemischen PSMA Expressionsprofiles von Patienten mit neu diagnostizierten, metastasierten Tumoren  des GI-Trakts. Anhand der Immunhistochemie Selektion von Patienten für ein PSMA-PET/CT mit anschließend visueller und semiquantitativer Bestimmung der PSMA Traceraktivität in Primärtumor und Metastasen. ","eudractNumber":null,"id":8165,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05547919","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-10-01T12:04:46+02:00","shortTitle":"PSMA in Gastrointestinal Tumors (GIPSMA, Focusing on Neuroendocrine Neoplasms)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Patienten-Typologisierung für ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positivem Mammakarzinom / PaTyp

VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":7720,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-12T14:28:59+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Patienten-Typologisierung für ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positiven MammaCa / PaTyp

VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":10616,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-13T08:39:41+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Onko Coaching und frühe Palliative Begleitung als patientenzentrierte Versorgungselemente in der Therapie nicht heilbarer Krebserkrankungen – OnCoPaTh
VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":6548,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2021-02-18T11:32:43+01:00","shortTitle":"Patientencoaching OncoPath","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"

Prophylaktische\nWirkung eines retromuskulären Netzes während Ileostomarückverlagerung auf die\nInzidenz von Narbenhernien – eine multizentrische randomisierte Patienten- und\nBeobachter-verblindete Studie

\n\n(P.E.L.I.O.N.\nTrial)
DRKS00027921
","eudractNumber":null,"id":9368,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-03-04T12:15:13+01:00","shortTitle":"Pelion","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Phase\nII trial of Pembrolizumab in COmbination with salvage\nchemotherapy for first-RElapsed or refractory classical Hodgkin lymphoma","eudractNumber":"2022-501306-35","id":8371,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04838652","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-12-04T09:29:44+01:00","shortTitle":"Pembro-CORE pilot","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"

Etablierung kontinuierlicher perioperativer\nBlutglucosemessungen zur Detektion metabolischer Veränderungen bei Patienten in\nder Viszeralchirurgie: Machbarkeits- und Etablierungsstudie

","eudractNumber":null,"id":11032,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-06-15T13:14:09+02:00","shortTitle":"PeriOPGlukose","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Anwendung von Privigen® bei sekundärer Immunschwäche: Eine multizentrische Beobachtungsstudie (IgPro10_5008)

NIS-Nr.:742
","eudractNumber":null,"id":9261,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-02-15T13:25:54+01:00","shortTitle":"Privigen","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}